Theravance reports real-world observational data for Vibativ

Theravance Biopharma Inc. (NASDAQ:TBPH) reported data from the U.S. TOUR (Telavancin Observational Use Registry) study in 1,063 patients with various

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE